semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 1.0-18.0,  Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination Therapy vs. Oseltamivir Alone for Hospitalised Paediatric Influenza Patients age 1 year to 18 years; body temperature higher than 38 °C; presence of one of the following symptoms-cough, sputum production, sore throat, rhinorrhoea, myalgia, headache, or fatigue presenting within 72 hours from symptom onset; laboratory-confirmed influenza infection (including rapid test or PCR-confirmed influenza A or B); and clinical requirement for hospitalisation. Antiviral treatment was initiated within 48 hours after admission  a history of allergy or contraindication to the study medications; the administration of medications with macrolides (ex: azithromycin, erythromycin), naproxen or neuraminidase inhibitor use within 72 hours; current use of any antibiotic; and the presence of an immunocompromised state due to steroid use, human immunodeficiency virus infection, chronic kidney disease, renal failure, chemotherapy or radiotherapy in half year, or innate immunodeficiency
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Ulcerative Colitis Crohn Disease Inflammatory Bowel Diseases Clinically stable patients, constant medicinal regimen throughout the study period. Refractory to mesalamine at least 6 weeks, or steroids at least 2 week, or immunomodulator at least 12 weeks or biologics at least 12 weeks therapy, medical cannabis at least 2 weeks before the study. 2. Patients will be included if they have mild to moderate disease defines as: 2.1 CD patients will be included if their symptoms score 4<between <16 on the Harvey-Bradshaw index (HBI) score, or HBI < 4 and calprotectin >250 2.2 UC patients will be included if their symptoms score >3between <11 on the SCCAI score, or UC patients with SCCAI <3 and calprotectin >250 3. Patients who agreed to refrain from over the counter (OTC) medications for lower GI symptoms and dietary supplements or other foods containing fermented live bacteria throughout the study period  Any proven current infection such as Clostridium difficile infection , positive stool culture, or parasites, in cases when a patient complains of diarrhea and have not preformed those tests in the past 6 months 2. Antibiotic use during participation in the study 3. Change in medication regimen before study initiation (see 2) or during the study 4. Inability to sign informed consent and complete study protocol 5. Pregnancy 6. Subjects with chronic conditions such as cancer, organ transplant subjects, advanced kidney or liver disease, systemic inflammatory conditions other than IBD. 7. Patients with ileostomy, pouch or short bowel
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Delirium Confusion Mental Status Change Back Pain Hip Pain Chronic Chest Pain Asthma COPD Cellulitis Soft Tissue Infections Cough Deep Vein Thrombosis Pulmonary Embolism Venous Thromboembolism Dyspnea Electrolyte Metabolism Abnormal Fever Failure to Thrive Weakness Protein-Calorie Malnutrition Headache Neck Pain Hypoxia Pneumonia Sepsis Syncope Vomiting Diarrhea Leg Pain Abdominal Pain Age 18 or older Adult patients admitted to General Medicine Services at Brigham and Women's Hospital during the 21-months study data collection period English speakers Patients who were diagnosed with any of the following conditions and symptoms upon admission Abdominal pain Altered mental status/ delirium / confusion Asthma / chronic obstructive pulmonary disease (COPD) Cellulitis / soft tissue infection Chest pain Cough  Not pregnant women, prisoners and institutionalized individuals
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  SARS-CoV-2 Pneumonia COVID-19 PositiveSARS-COV-2 RT-PCR in hospitalized patients in University Hospital Farhat Hached in Sousse Tunisia Had either not received hydroxychloroquine before or had received hydroxychloroquine for at least 1 day and could tolerate a dose of 200 mg of hydroxychloroquine/day  Unableto take oral medication, pregnancy or breast feeding, immune-compromised patients Contraindicationto the studied medications
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Postoperative Nausea acute pancreatitis  systemic disease as hypertension or diabetes
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Enterococcal Bacteremia Hospitalized patient ≥1 positive blood culture with Enterococcus spp. (VRE or VSE) during hospitalization bacterial isolate(s) is/are available for further characterization Repeat blood culture(s) within 7 days from the first positive culture  Cultures obtained from patients not admitted to the hospital Isolate(s) not available for further studies
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Post-operative Milestones English-speaking Female Patients undergoing benign hysterectomy or myomectomy via low-transverse laparotomy  ASA classification of three or higher Malignancy Non-English speaking
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Irritable Bowel Syndrome Abdominal Pain Autonomic Nervous System Imbalance Adults, aged 18-60 years, who are able to provide written, informed consent Patients must meet Rome IV for IBS, confirmed by a gastroenterologist who specializes in functional GI disorders. Any of the IBS bowel habit subtypes (diarrhea, constipation, mixed bowel habits, unclassified) will be allowed Average daily worst abdominal pain score between 4 and 8 (on a 0-10-point rating scale) Minimum of 2 days of abdominal pain/week prior to starting trial At least moderate IBS symptom severity with an IBS-SSS of at least 175 (total score range 0-500) If receiving pharmacologic therapy for abdominal pain associated with IBS, doses must be stable for at least 60 days prior to enrollment in the trial If receiving pharmacologic therapy for IBS that does not have an effect on abdominal pain, doses must be stable for at least 30 days prior to enrollment in the trial. Mandatory  Patients under the age of 18 years or over the age of 60 years Patients who cannot provide informed consent or do not speak English Co-morbid, organic medical conditions associated with abdominal pain, including: Inflammatory bowel disease, chronic liver disease, peptic ulcer disease, celiac disease, diverticulitis, appendicitis, colorectal cancer, endometriosis, pregnancy, other intestinal or extra-intestinal malignancies. Patients with overlapping functional GI disorders (i.e. functional dyspepsia) will not be excluded as long as IBS is their predominant disorder History of surgery involving CN V, VII, IX, or X History of abdominal surgeries other than appendectomy or cholecystectomy at least 6 months before entry into trial Patients on chronic opioids, benzodiazepines, or with illicit substance use Patients with underlying neurologic conditions, including history of: seizures, CVA, uncontrolled migraines, traumatic brain injury, multiple sclerosis Patients with underlying psychiatric conditions Patients with dermatologic conditions affecting the ear, face, or neck region (i.e. psoriasis), or with cuts or abrasions to the external ear that would interfere with needle placement Patients with hemophilia or other bleeding disorders
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  COVID-19 Pneumonia Convalescent Plasma (Donors) Signed informed consent At least positive for 1 q-PCR test for SARS-CoV-2 days of COVID-19 clinical remission Positive serologic test for SARS-CoV-2 Requirements to donate according to NOM-253-SSA1-2012 To accept sample storing for future study (Receptors) Signed informed consent provided by the patient, legal guardian or the health provider if not available Patients hospitalized in an ICU dedicated to the treatment of COVID-19 patients At least positive for 1 q-PCR test for SARS-CoV-2  Positive pregnancy test Patients in lactation Informed consent not signed Patients involved in other treatment protocols Patients on immunomodulatory drugs (DMARDs, monoclonal antibodies or smal molecule drugs)
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Diarrhea Calprotectin age more than 18 hear Diarrhea more than 3 time per day after admitted in hospital more than 72 hours  intraabdominal pressure more than 12 mmHg patient on chemotherapy with neutropenia ,ANC less than 1,000/mm3 patients whose definite diagnosis cannot be obtained
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Ventricular Arrhythmia Ventricular Tachycardia Premature Ventricular Contraction (PVC) Cardiomyopathy All patients undergoing catheter ablation for ventricular tachycardia (VT) or premature ventricular contractions (PVCs)
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Covid19 Pneumonia Adult patients ≥18, and non-pregnant women Severe or critical COVID-19 disease define by one or more of the following: blood oxygen saturation ≤ 94% on supplemental oxygen by nasal cannula at least 3 L/min, non-rebreathing mask (NRO2-mask) or on noninvasive ventilation; and pulmonary infiltrates with >50% increase within 24 to 48 hours in chest-X-ray or chest CT. Life-threatening disease was defined as one or more of the following: respiratory failure on mechanical ventilation with PaO2 / FiO2 less than 300 mm Hg, septic shock, and/or multiple organ dysfunction days from the onset of symptoms or ≤ 7 days on mechanical ventilation. -  More than 10 days from symptoms onset or more than 7 days on mechanical ventilation Pregnancy Contraindication for plasma infusion because anaphylaxis history Patients with high risk of circulatory overload Limitation of therapeutic efforts Refractory shock define by norepinephrine dose more than 1 ug/k/min SOFA score more than 15 points at the moment of the protocol i Coagulopathy with requirements of plasma infusion
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-79.0,  Viral Disease Male or female participants between the ages of 18 and 79 years. 2. Confirmed SARS-CoV-2 infection. 3. Hospitalized for COVID-19. 4. Symptoms consistent with COVID-19 indicated by at least 1 of the following: fever, cough, sore throat, malaise, headache, muscle pain, shortness of breath, new loss of taste and smell, nausea, chills, fatigue, rhinorrhea, diarrhea, vomiting or radiographic infiltrates by imaging consistent with COVID-19 5. Total body weight >=50 kg (110 lb), BMI <40 kg/m2; BMI <35 kg/m2 for 76 years  Evidence of critical illness, defined by at least one of the following: Respiratory failure, Multi-organ dysfunction/failure, Cardiac failure or septic shock 2. Participants that are anticipated by the study Investigator to progress to critical disease, including mechanical ventilation, within 24 hours of enrolment 3. Participants with pre-existing moderate to severe cardiovascular disease, uncontrolled diabetes, or severe asthma or severe COPD. 3.Participants with a known medical history of recent acute or chronic liver disease (other than NASH), chronic or active hepatitis B or C infection, or primary biliary cirrhosis. 4.Participants with a known medical history of ischemic heart disease, heart failure, dysrhythmia or other pre-existing cardiac condition. 5. Participants with known HIV infection, acute or chronic history of hepatitis B or C. 6.Participants with a known medical history of recurrent seizures. 7. Participants with history of venous thromboembolic event, including deep venous thrombosis or pulmonary embolism 8.Confirmed concurrent active systemic infection other than COVID-19. 9.Current diagnosis of cancer, unless in remission and untreated. 10.Other medical or psychiatric condition including recent or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation 11.Females who are pregnant or breastfeeding
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Covid19 Aged ≥ 18 years Admitted to ICU within 72 hours Having confirmed or highly suspected COVID-19 infection (positive RT-PCR and/or computed tomography) Having acute hypoxemic respiratory failure with a [PaO2/FiO2] ratio between 100 mmHg and 300 mmHg Having given free and informed written consent Being affiliated with or benefiting from a social security scheme  Unable to achieve a prone position for mobility reasons Unable to achieve a prone position due to agitation whatever the cause With clinical occlusive syndrome in order to limit the risk of inhalation Having a contraindication to the use of the esophageal catheter Having signs of respiratory distress or disturbance of consciousness requiring intubation within the next hours Having hypercapnia indicating the use of non-invasive ventilation (PaO2> 50 mmHg) Having severe hypoxemia defined by PaO2 / FiO2 <100mmHg Ongoing pregnancy or breastfeeding Subject to a measure for the protection of justice
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Respiratory Distress Syndrome, Adult endotracheal tube or tracheostomy in place and mechanically ventilated for ≤7 days; 2. admitted to a participating ICU 3. radiologic evidence of bilateral pulmonary infiltrates not fully explained by pleural effusions, atelectasis, or hydrostatic pulmonary edema 4. P/F ratio <200 with PEEP ≥8 cm H2O; If ABG values are not available, the P/F ratio may be inferred from SpO2 values based on Table 3 from Brown et al as long as following conditions are met: 1. SpO2 values are 80-96% 2. SpO2 is measured ≥10 min after any change in FIO2 3. PEEP is ≥ 8 cm H2O 4. the pulse oximeter waveform tracing is adequate 5. the qualifying inferred P/F ratio is confirmed 1-6h after initial determination. 5. access to an LAR to provide consent. 6. 3 AND 4 must be met within 48h of enrollment and randomization, not be fully explained by hydrostatic pulmonary edema, and must have occurred within 7 days onset of a condition associated with ARDS Patients may be enrolled and decision about randomization delayed if all other than P/F ratio < 200 are met and then randomized if and when the P/F ratio < 200 (as long as this occurs within 48h of randomization)  Missed ARDS window (>48hrs) 2. Missed NMB window: (>12 hrs) 3. Missed mechanical ventilation window (>7 days) 4. Refractory hypotension (> 0.2 mcg/kg/min of norepinephrine or equivalent dose for 6 h or longer) 5. Core temperature <35.5°C while not receiving CRRT 6. Patient is unable to give consent and no Legally authorized representative is available 7. Significant, active bleeding (>3u blood products and/or surgical/IR intervention) 8. Platelets <10K/mm3 (uncorrected) 9. Active hematologic malignancy 10. Skin process that precludes cooling device 11. Moribund, not likely to survive 72h 12. Pre-morbid condition makes it unlikely that patient will survive 28 days 13. Do Not Resuscitate status 14. Not likely to remain intubated for ≥48h 15. Physician of record unwilling to participate 16. Severe underlying lung disease 1. On home O2 2. On BIPAP (except for OSA) 3. Prior lung transplantation 17. Pregnant 18. BMI >50 kg/m2 19. Known NYHA class IV heart disease 20. Acute Coronary Syndrome past 30 days (MI, unstable angina) 21. Cardiac arrest within 30 days of enrollment 22. Burns over >20% of the body surface 23. Severe chronic liver disease (Child-Pugh score 12-15) 24. Previously randomized in CHILL study